Abstract: Chimeric proteins comprising an N-terminal domain derived from an N-terminal nucleotide binding domain of TDP-43 and a C-terminal domain derived from a splicing repressor are described. These proteins may be administered to a subject to treat or prevent disease manifesting TDP-43 proteinopathy such as inclusion body myocytosis, amyotrophic lateral sclerosis (ALS), or frontotemporal dementia (FTD).

Abstract: An adenovirus or adenoviral vector is described that includes a non-native nucleotide sequence capable of expressing a chimeric protein comprising an N-terminal nucleotide binding domain of transactivation response element DNA-binding protein (TDP-43), a C-terminal domain derived from a splicing repressor, and an autoregulatory element. Methods of using the adenovirus or adenoviral vector to treat degenerative diseases such as inclusion body myocytosis, amyotrophic lateral sclerosis, and frontotemporal dementia are also described.

Abstract: Chimeric proteins comprising an N-terminal domain derived from an N-terminal nucleotide binding domain of TDP-43 and a C-terminal domain derived from a splicing repressor are described. These proteins may be administered to a subject to treat or prevent disease manifesting TDP-43 proteinopathy such as inclusion body myocytosis, amyotrophic lateral sclerosis (ALS), or frontotemporal dementia (FTD).

Abstract: Chimeric proteins comprising an N-terminal domain derived from an N-terminal nucleotide binding domain of TDP-43 and a C-terminal domain derived from a splicing repressor are described. These proteins may be administered to a subject to treat or prevent disease manifesting TDP-43 proteinopathy such as inclusion body myocytosis, amyotrophic lateral sclerosis (ALS), or frontotemporal dementia (FTD).

Abstract: Described herein are methods for detecting, characterizing, preventing, and treating metabolic diseases, including obesity and obesity-associated disorders such as diabetes.

Abstract: Described herein are methods for detecting, characterizing, preventing, and treating metabolic diseases, including obesity and obesity-associated disorders such as diabetes.

Abstract: The invention provides transgenic non-human animals, such as transgenic rodents and transgenic non-human mammalian cells harboring a transgene which eliminates the expression of a &bgr;-secretase BACE1. Also provided are methods of diagnosing neurodegenerative diseases including Alzheimer's Disease as well as methods of identifying agents which modulate or treat Alzheimer's Disease and related pathology.

Abstract: Transgenic non-human animals, including, for example, transgenic rodents and transgenic non-human mammalian cells, which harbor a transgene that eliminates the expression of the &bgr;-secretase, BACE1, are provided. In addition, antibodies specific for BACE1 are provided. Also provided are methods of diagnosing a neurodegenerative disease, including Alzheimer's disease, and methods of identifying agents that modulate or treat Alzheimer's disease and related pathology.

Abstract: A variable timing sequencer for producing sets of data which correspond to different current states of the sequencer, wherein the interval of each such set of data corresponds to said current state and user input, and said current state is determined by a previous state and input data. This separation of the time domain sequencing from the functional sequencing allows operation of functional components at lower frequencies than the timing components and the increase of effective memory density. The ability to affect both current state and interval by means of an input permits the sequencer to be used in a variety of conditions and applications with a minimum amount of reprogramming.